The worldwide pharmaceutical business skilled 0.3% decline within the variety of 3D printing-related patent functions in Q3 2022 in contrast with the earlier quarter. The whole variety of 3D printing-related grants dropped by 7% in Q3 2022, in response to GlobalData’s Patent Analytics.
Notably, the variety of 3D printing-related patent functions within the pharmaceutical business was 336 in Q3 2022, versus 337 within the prior quarter.
The highest 5 corporations accounted for 15% of patenting exercise
Evaluation of patenting exercise by corporations reveals that Arkema filed probably the most 3D printing patents inside the pharmaceutical business operations and applied sciences sector in Q3 2022. The corporate filed 23 3D printing-related patents within the quarter, in contrast with 18 within the earlier quarter. It was adopted by Johnson & Johnson with 10 3D printing patent filings, Jabil (7 filings), and 3D Programs (6 filings) in Q3 2022.
Patenting exercise was pushed by the US with a 26% share of complete patent filings
The biggest share of 3D printing associated patent filings within the pharmaceutical business in Q3 2022 was within the US with 26%, adopted by China (20%) and South Korea (10%). The share represented by the US was 1% decrease than the 27% share it accounted for in Q2 2022.